Long-term body weight outcomes of antidepressant-environment interactions

Molecular Psychiatry

Volumn 16, Issue 3, 2011, Pages 265-272

  Mastronardi, C ^a   Paz Filho, G J ^a   Valdez, E ^b   Maestre Mesa, J ^b   Licinio, J ^a   Wong, M L ^a  

^a Biology and Environment   (Australia)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

antidepressant; behavior; body size; body weight; diet; restraint stress

Indexed keywords

FLUOXETINE; IMIPRAMINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BODY SIZE; CALORIC INTAKE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG SENSITIZATION; DRUG USE; IMMOBILIZATION STRESS; LIPID DIET; LOCOMOTION; NONHUMAN; OBESITY; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; RISK FACTOR; SHORT COURSE THERAPY; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BODY WEIGHT; DIETARY FATS; DISEASE MODELS, ANIMAL; EATING; ENERGY INTAKE; ENVIRONMENT; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RESTRAINT, PHYSICAL; STATISTICS, NONPARAMETRIC; STRESS, PSYCHOLOGICAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 79951812002     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2010.122     Document Type: Article

References (38)

1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617-627. (Pubitemid 40973437)
2. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8-19.
3. Vos T, Haby MM, Barendregt JJ, Kruijshaar M, Corry J, Andrews G. The burden of major depression avoidable by longer-term treatment strategies. Arch Gen Psychiatry 2004; 61: 1097-1103. (Pubitemid 39463410)
4. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998; 4: 1241-1243. (Pubitemid 28512100)
5. Bulloch AG, Patten SB. Non-adherence with psychotropic medications in the general population. Soc Psychiatry Psychiatr Epidemiol 2010; 45: 47-56.
6. Wang PS, Simon G, Kessler RC. The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res 2003; 12: 22-33. (Pubitemid 36675445)
7. Milane MS, Suchard MA, Wong ML, Licinio J. Modeling of the temporal patterns of fluoxetine prescriptions and suicide rates in the United States. PLoS Med 2006; 3: e190.
8. Olfson M, Marcus SC. National patterns in antidepres-sant medication treatment. Arch Gen Psychiatry 2009; 66: 848-856.
9. Mant A, Rendle VA, Hall WD, Mitchell PB, Montgomery WS, McManus PR et al. Making new choices about antidepressants in Australia: the long view 1975-2002. Med J Aust 2004; 181: S21-S24. (Pubitemid 39341672)
10. Moore M, Yuen HM, Dunn N, Mullee MA, Maskell J, Kendrick T. Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ 2009; 339: b3999.
11. Olie JP, Elomari F, Spadone C, Lepine JP. Antidepressants consumption in the global population in France. Encephale 2002; 28: 411-417. (Pubitemid 35339397)
12. Papakostas GI. Limitations of contemporary antidepressants: tolerability. J Clin Psychiatry 2007; 68(Suppl 10): 11-17. (Pubitemid 47507832)
13. Serna MC, Cruz I, Real J, Gasco E, Galvan L. Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database. Eur Psychiatry 2010; 25: 206.
14. McAllister EJ, Dhurandhar NV, Keith SW, Aronne LJ, Barger J, Baskin M et al. Ten putative contributors to the obesity epidemic. Crit Rev Food Sci Nutr 2009; 49: 868-913.
15. File SE, Tucker JC. Behavioral consequences of antidepres-sant treatment in rodents. Neurosci Biobehav Rev 1986; 10: 123-134. (Pubitemid 16064911)
16. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-809. (Pubitemid 36962615)
17. Wong ML, Licinio J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov 2004; 3: 136-151. (Pubitemid 38239775)
18. Antelman SM, Chiodo LA. Repeated antidepressant treatments induce a long-lasting dopamine autoreceptor subsensitivity: is daily treatment necessary for clinical efficacy? Psychopharmacol Bull 1981; 17: 92-94. (Pubitemid 11180481)
19. Brady LS, Gold PW, Herkenham M, Lynn AB, Whitfield Jr HJ. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin- releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res 1992; 572: 117-125.
20. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepres-sant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104-9110. (Pubitemid 32042912)
21. Yirmiya R, Pollak Y, Barak O, Avitsur R, Ovadia H, Bette M et al. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuro-psychopharmacology 2001; 24: 531-544. (Pubitemid 32244314)
22. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61(Suppl 11): 37-41. (Pubitemid 30616693)
23. Glassman AH. Depression and cardiovascular comorbidity. Dialogues Clin Neurosci 2007; 9: 9-17. (Pubitemid 46607127)
24. Papakostas GI. Tolerability of modern antidepressants. J Clin Psychiatry 2008; 69(Suppl E1): 8-13.
25. Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry 2001; 62: 256-260. (Pubitemid 32428764)
26. Cascade E, Kalali AH, Kennedy SH. Real-world data on SSRI antidepressant side effects. Psychiatry (Edgmont) 2009; 6: 16-18.
27. Hu XH, Bull SA, Hunkeler EM, Ming E, Lee JY, Fireman B et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004; 65: 959-965.
28. Schwartz TL, Nihalani N, Jindal S, Virk S, Jones N. Psychiatric medication-induced obesity: a review. Obes Rev 2004; 5: 115-121. (Pubitemid 38623165)
29. Chotiwat C, Harris RB. Antagonism of specific corticotropin-releasing factor receptor subtypes selectively modifies weight loss in restrained rats. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1762-R1773.
30. Garcia A, Marti O, Valles A, Dal-Zotto S, Armario A. Recovery of the hypothalamic-pituitary-adrenal response to stress. Effect of stress intensity, stress duration and previous stress exposure. Neuroendocrinology 2000; 72: 114-125.
31. Chotiwat C, Kelso EW, Harris RB. The effects of repeated restraint stress on energy balance and behavior of mice with selective deletion of CRF receptors. Stress 2010; 13: 203-213.
32. Antelman SM, DeGiovanni LA, Kocan D, Perel JM, Chiodo LA. Amitriptyline sensitization of a serotonin-mediated behavior depends on the passage of time and not repeated treatment. Life Sci 1983; 33: 1727-1730. (Pubitemid 13010016)
33. Lace JW, Antelman SM. Cortical beta-adrenergic subsensi-tivity after desmethylimipramine may depend on the passage of time rather than daily treatment. Brain Res 1983; 278: 359-361. (Pubitemid 14206174)
34. Antelman SM, Levine J, Gershon S. Time-dependent sensitization: the odyssey of a scientific heresy from the laboratory to the door of the clinic. Mol Psychiatry 2000; 5: 350-356. (Pubitemid 30455947)
35. Chiodo LA, Antelman SM. Electroconvulsive shock: progressive dopamine autoreceptor subsensitivity independent of repeated treatment. Science 1980; 210: 799-801. (Pubitemid 11194035)
36. Atkinson T. Lifestyle drug market booming. Nat Med 2002; 8: 909.
37. Licinio J, Wong ML. Depression and obesity treatments are life saving. Nat Med 2002; 8: 1336. (Pubitemid 36019401)
38. CDC. Behavioral Risk Factor Surveillance System Survey Data. US Department of Health and Human Services, Centers for Disease Control and Prevention: Atlanta, GA, 2008.